top of page
ResolveBioLogo-final-09.png
2

News and Events

April 7, 2026

Resolve Therapeutics and Institut Pasteur Collaborate to Identify Cell-Free RNA Triggers in Autoimmunity

Read Press Release

Novemeber 19, 2025

Resolve Therapeutics to Present at International Symposium on Circulating Nucleic Acids in Plasma and Serum (CNAPS)

Read Press Release

May 28, 2025

Resolve Therapeutics and Duke Medical School Initiate Observational Study of Cell-free RNA in Polytrauma Patients.

Read Press Release

May 13, 2024

Resolve Therapeutics Publishes Results of RSLV-132 Phase 2 Long COVID Study

Read Press Release

February 12, 2024

Resolve Therapeutics Announces Publication of Lupus Clinical Trial Results

Read Press Release

November 14, 2022

Resolve Therapeutics Completes Enrollment of Phase 2 Long Covid Clinical Trial

Read Press Release

June 23, 2021

Resolve Therapeutics Receives FDA Approval to Initiate Phase 2 Clinical Trial of RSLV-132 in Long Covid Patients

Read Press Release

December 8, 2020

RSLV-132 Demonstrates Clinically Meaningful Improvement in Patients With Systemic Lupus Erythematosus in Phase 2a Clinical Trial

Read Press Release

December 8, 2020

Resolve Therapeutics Publishes Positive Sjögren’s Syndrome Clinical Trial Results

Read Press Release

July 22, 2019

Resolve Therapeutics Announces Completion of Enrollment for Phase 2a Study of RSLV-132 for the Treatment of Lupus

Read Press Release

June 13, 2019

Resolve Therapeutics Announces RSLV-132 Significantly Reduces Fatigue in Phase II Study of Patients with Sjögren’s Syndrome

Read Press Release

June 10, 2019

Resolve Therapeutics To Present Phase II Data on Lead Product Candidate RSLV-132 at the 2019 EULAR European Congress of Rheumatology

Read Press Release

Meet Us at Upcoming Conferences

BIO International Convention

San Diego, CA

June  22-25, 2026

Learn More

European Stroke Organisation 2026

 Maastrich, NL 
May 6-8, 2026

Learn More
bottom of page